Since the beginning of the AIDS epidemic, the Bronx has been one of the epicenters of HIV infection within the United States. The Einstein/Montefiore Medical Center (MMC) CFAR serves the Bronx, a borough of New York City that remains at the leading edge of the AIDS epidemic. The 20,627 known individuals living with HIV/AIDS in the Bronx represent 2.6% of the estimated national caseload. Investigators at Einstein and MMC have developed a broad-based research effort that is examining multiple and diverse aspects of the basic science, clinical manifestations, behavioral aspects and epidemiology of HIV and HIV-related diseases. The AIDS research effort at Einstein and MMC is led by over 70 principal investigators who are supported by greater than 25 million dollars of annual funding from the NIH. The leadership and infrastructure provided by the Einstein/MMC CFAR has been extremely successful in incorporating the diverse AIDS investigative effort at Einstein/MMC into a unified and highly interactive Program. During the past four years of NIH funding, the Einstein/MMC CFAR has been extremely successful in implementing its proposed Specific Aims and markedly increasing collaborative research projects among Einstein basic investigators and MMC clinical investigators, establishing well-run and highly-used Core facilities and providing intellectual, scientific, technical and financial help to foster and nurture the careers of junior AIDS investigators. Through internal and external recruitment, the CFAR has increased the number of investigators involved in AIDS-related research from 38 to 72. During this time, CFAR investigators have published over 700 papers almost 10% of which specifically acknowledge support from the CFAR. The CFAR has dramatically increased institutional support for AIDS-related research at Einstein, which has contributed almost 3.4 million dollars to recruit CFAR investigators, subsidize CFAR cores, renovate CFAR Core space and purchase equipment to expand CFAR Core services. In addition, the administration has committed another one million dollars to recruit additional AIDS researchers to Einstein. We have engaged in detailed Strategic Planning sessions using SWOT analysis to address our weaknesses and leverage our strengths into new areas. A major accomplishment that is directly attributed to this process is the dramatic expansion of our international AIDS research programs in developing countries. Four years ago we had no active International AIDS research programs. We now have active programs in South Africa, Rwanda, Ethiopia, India, Bangladesh and Guatemala. These and other accomplishments and scientific advances made by Einstein/MMC CFAR investigators during this funding period represent a very high level of value-added benefit from the Einstein/MMC CFAR.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
3P30AI051519-10S1
Application #
8628346
Study Section
Special Emphasis Panel (ZAI1-EC-A (J1))
Program Officer
Namkung, Ann S
Project Start
2002-04-01
Project End
2014-04-30
Budget Start
2013-05-01
Budget End
2014-04-30
Support Year
10
Fiscal Year
2013
Total Cost
$834,723
Indirect Cost
$296,287
Name
Albert Einstein College of Medicine
Department
Pediatrics
Type
Schools of Medicine
DUNS #
110521739
City
Bronx
State
NY
Country
United States
Zip Code
10461
Lankowski, Alexander J; Bien-Gund, Cedric H; Patel, Viraj V et al. (2018) PrEP in the Real World: Predictors of 6-Month Retention in a Diverse Urban Cohort. AIDS Behav :
Kirichenko, Tatiana V; Myasoedova, Veronika A; Shimonova, Tatiana E et al. (2018) Atherosclerosis in subjects newly diagnosed with human immunodeficiency virus infection. Biosci Rep 38:
Auld, Sara C; Shah, N Sarita; Mathema, Barun et al. (2018) Extensively drug-resistant tuberculosis in South Africa: genomic evidence supporting transmission in communities. Eur Respir J 52:
Harbut, Michael B; Yang, Baiyuan; Liu, Renhe et al. (2018) Small Molecules Targeting Mycobacterium tuberculosis Type II NADH Dehydrogenase Exhibit Antimycobacterial Activity. Angew Chem Int Ed Engl 57:3478-3482
Patel, Viraj V; Dange, Alpana; Rawat, Shruta et al. (2018) Barriers to HIV Testing Among Men Who Have Sex With Men in India Reached Online: Implications for Interventions. J Acquir Immune Defic Syndr 78:e30-e34
Vilchèze, Catherine; Kim, John; Jacobs Jr, William R (2018) Vitamin C Potentiates the Killing of Mycobacterium tuberculosis by the First-Line Tuberculosis Drugs Isoniazid and Rifampin in Mice. Antimicrob Agents Chemother 62:
Patel, Viraj V; Ginsburg, Zoë; Golub, Sarit A et al. (2018) Empowering With PrEP (E-PrEP), a Peer-Led Social Media-Based Intervention to Facilitate HIV Preexposure Prophylaxis Adoption Among Young Black and Latinx Gay and Bisexual Men: Protocol for a Cluster Randomized Controlled Trial. JMIR Res Protoc 7:e11375
Shah, N Sarita; Auld, Sara C; Brust, James C M et al. (2017) Transmission of Extensively Drug-Resistant Tuberculosis in South Africa. N Engl J Med 376:243-253
Heo, Moonseong; Litwin, Alain H; Blackstock, Oni et al. (2017) Sample size determinations for group-based randomized clinical trials with different levels of data hierarchy between experimental and control arms. Stat Methods Med Res 26:399-413
Felsen, Uriel R; Cunningham, Chinazo O; Heo, Moonseong et al. (2017) Expanded HIV Testing Strategy Leveraging the Electronic Medical Record Uncovers Undiagnosed Infection Among Hospitalized Patients. J Acquir Immune Defic Syndr 75:27-34

Showing the most recent 10 out of 531 publications